The Type 1 Diabetes Prevention Trial, also known as the Intranasal Insulin Trial (INIT II), is part of a coordinated global effort to develop a vaccine for type 1 diabetes. The trial, which began in 2006, is jointly funded by the National Health and Medical Research Council (NHMRC) and the Juvenile Diabetes Research Foundation (JDRF), through the Diabetes Vaccine Development Centre (DVDC).
The trial is designed to determine if the onset of type 1 diabetes can be delayed or prevented by a nasal insulin vaccine. Therefore, if the trial was successful it would benefit people at risk for type 1 diabetes by forestalling or preventing the development of type 1 diabetes in them.
The trial has a strict inclusion and exclusion criteria that participants need to meet in order to participate. Anyone aged between 4-30 years who has a first-degree (mother, father, brother, sister, son, daughter) or second-degree (aunt, uncle, grandmother, grandfather, half-brother, half-sister) relative with type 1 diabetes can participate. If the relative with type 1 diabetes is your grandmother, grandfather, aunt, uncle, niece, nephew, half-sister or half-brother, i.e. a second degree relative, you need to be aged 4-20 years to participate. The first step is to have a free blood test for antibodies that indicate the risk of getting type 1 diabetes.
FOR MORE INFORMATION PLEASE CONTACT:
Claire Wolczak (02) 9295 8359, dvdc@dvdc.org.au
www.stopdiabetes.com.au
This study has been approved by Melbourne Health Human Research Ethics Committee.
